Literature DB >> 2297509

Oral albendazole for the treatment of cutaneous larva migrans.

S K Jones1, N J Reynolds, S Oliwiecki, R R Harman.   

Abstract

Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side-effects and should, we feel, become the treatment of choice for this condition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297509     DOI: 10.1111/j.1365-2133.1990.tb08245.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  2 in total

1.  Three clinical cases of cutaneous larva migrans.

Authors:  Tae-Heung Kim; Byeung-Song Lee; Woon-Mok Sohn
Journal:  Korean J Parasitol       Date:  2006-06       Impact factor: 1.341

2.  Two imported cases of cutaneous larva migrans.

Authors:  J W Park; S J Kwon; J S Ryu; E K Hong; J U Lee; H J Yu; M H Ahn; D Y Min
Journal:  Korean J Parasitol       Date:  2001-03       Impact factor: 1.341

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.